BECLOMETASONE dipr.100mcg/FORMOTEROL fum. 6mcg/puff 120p,aer
Valid Article
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
BECLOMETASONE/FORMOTEROL, aerosol
- In the WHO list of Essential Medicines 2023 (Therapeutic alternative to budesonide + formoterol)
Therapeutic Action
Combination of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) inhaled bronchodilator:
- Beclometasone: a glucocorticoid with anti-inflammatory effects in the lungs, resulting in reduced asthma symptoms and exacerbations, with less adverse effects compared to systemic corticosteroids.
- Formoterol: a selective beta2-adrenergic agonist that produces relaxation of bronchial smooth muscle in patients with reversible airways obstruction. Its bronchodilatory effect begins rapidly, within 1-3 minutes after inhalation, and lasts for up 12 hours with a single dose.
Indications
Maintenance and symptomatic treatment of chronic asthma.
For adults aged 18 years and older.
Instructions for use
The combination of beclometasone and formoterol is available in two forms for inhalation:
- Pressurised Metered-Dose Inhaler (MDI): a small canister containing a mixture of the medicine and pressurised propellant. The pressure from the propellant delivers the medicine when the canister is pushed down into the boot/actuator.
- Dry-Powder Inhaler (DPI): a breath-actuated device that delivers the medicine as a fine, dry powder contained in a capsule or blister, which is punctured by the device before use.
Manufacturers may express the content per puff as a "metered dose" (the quantity of the drug in the device metering chamber, excluding the valve) or as a "delivered dose" (the quantity of drug delivered to the user, excluding the mouthpiece). Always refer to the product leaflet.
The inhalers generally supplied by MSF are pressurised metered-dose inhalers (MDI). Refer to the information leaflet for appropriate instructions for use according to the inhaler model.
The pressurised metered-dose inhalers are CFC free. Chlorofluorocarbons (CFCs) are harmful to the ozone layer, and HFA (hydrofluoroalkane) propellants are a more effective, environmentally friendly alternative.
Precautions for Use
Do not use for the treatment of an acute asthma attack.
Do not administer in children.
In patients who have difficulty coordinating the actuation on the metered-dose inhaler and inhalation (e.g elderly patients), use an inhalation chamber/spacer to facilitate administration and improve the effectiveness of the product.
Do not use any mouthpiece other than the one provided with the inhaler.
Transport Dangerous Goods
UN transport code:
- UN 1950 - Aerosols, non-flammable (each not exceeding 1 L capacity)
- Transport Class 2.2 - Non-flammable, non-toxic gases
Transport is only regulated for large quantities of aerosols.
Storage
- Before first use: keep in upright position between 2ºC and 8°C for a maximum of 18 months. Do not freeze.
- After first use: below 25ºC for a maximum of 3 months
- Read the manufacturer's instructions on the packaging.
- Shelf life: 21 months. The remaining shelf life at delivery should be at least 1/3 of the total shelf life
- Used pressurised aerosols: do not pierce or incinerate. Empty any residual gas, then dispose of by burying.
![[EMEQSPAC2--] SPACER, 155 ml, + silicone masks size1 & size2 + mouthpiece](/web/image/product.template/572883/image_256/%5BEMEQSPAC2--%5D%20SPACER%2C%20155%20ml%2C%20%2B%20silicone%20masks%20size1%20%26%20size2%20%2B%20mouthpiece?unique=30fe079)
![[SMSUSPAC4M-] SPACER, single patient, medium mask](/web/image/product.template/569846/image_256/%5BSMSUSPAC4M-%5D%20SPACER%2C%20single%20patient%2C%20medium%20mask?unique=4b7448d)